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Summary
Background Stomach cancer is a major health problem in many countries. Understanding the current burden of 
stomach cancer and the differential trends across various locations is essential for formulating effective preventive 
strategies. We report on the incidence, mortality, and disability-adjusted life-years (DALYs) due to stomach cancer in 
195 countries and territories from 21 regions between 1990 and 2017.
Methods Estimates from GBD 2017 were used to analyse the incidence, mortality, and DALYs due to stomach cancer 
at the global, regional, and national levels. The rates were standardised to the GBD world population and reported per 
100 000 population as age-standardised incidence rates, age-standardised death rates, and age-standardised DALY 
rates. All estimates were generated with 95% uncertainty intervals (UIs).
Findings In 2017, more than 1·22 million (95% UI 1·19–1·25) incident cases of stomach cancer occurred worldwide, 
and nearly 865 000 people (848 000–885 000) died of stomach cancer, contributing to 19·1 million (18·7–19·6) DALYs. 
The highest age-standardised incidence rates in 2017 were seen in the high-income Asia Pacific (29·5, 28·2–31·0 per 
100 000 population) and east Asia (28·6, 27·3–30·0 per 100 000 population) regions, with nearly half of the global 
incident cases occurring in China. Compared with 1990, in 2017 more than 356 000 more incident cases of stomach 
cancer were estimated, leading to nearly 96 000 more deaths. Despite the increase in absolute numbers, the worldwide 
age-standardised rates of stomach cancer (incidence, deaths, and DALYs) have declined since 1990. The drop in the 
disease burden was associated with improved Socio-demographic Index. Globally, 38·2% (21·1–57·8) of the age-
standardised DALYs were attributable to high-sodium diet in both sexes combined, and 24·5% (20·0–28·9) of the 
age-standardised DALYs were attributable to smoking in males.
Interpretation Our findings provide insight into the changing burden of stomach cancer, which is useful in planning 
local strategies and monitoring their progress. To this end, specific local strategies should be tailored to each country’s 
risk factor profile. Beyond the current decline in age-standardised incidence and death rates, a decrease in the absolute 
number of cases and deaths will be possible if the burden in east Asia, where currently almost half of the incident 
cases and deaths occur, is further reduced.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Stomach cancer is an important contributor to the global 
burden of cancer,1 and less than a century ago it was the 
most common cancer in the world.2 Since then, the 
incidence and mortality rates of stomach cancer have 
fallen.3 However, this trend has shown signs of change; 
for example, some researchers suggest that in the USA, 
the rates of stomach cancer might be increasing among 
younger age groups (ie, <50 years) and predict that this 
increase might reverse the overall decline in the 
incidence of stomach cancer.4 More than 90% of stomach 
cancers are adenocarcinomas, and, depending on 
whether the tumour is located near the gastro-
oesophageal junction (cardia) or away from it, they are 
subdivided into cardia and non-cardia tumours, 
respectively.1 The decreasing trend of stomach cancer 
incidence and mortality in most populations is due to the 
falling rates of non-cardia stomach cancer and has been 
linked to a decline in Helicobacter pylori infection rates.5,6 
H pylori is a known carcinogen7 for non-cardia stomach 
cancer, which probably once infected most adults during 
their life course.8 Improved socio-economic status, 
hygienic practices, and widespread antibiotic use have 
led to a decrease in infection rates.9
The epidemiology of stomach cancer has substantial 
geographical heterogeneity, and its incidence can 
vary 5-fold to 10-fold between high-risk and low-risk 
countries.10 Part of this geographical variation correlates 
with H pylori infection rates across populations; 
however, a number of environmental factors also 
contribute to the risk of stomach cancer. Cigarette 
smoking has been shown to be a risk factor for both 
cardia and non-cardia stomach cancers.11 Evidence 
suggests that salt and salt-preserved foods might 
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increase the risk of stomach cancer.12,13 Both types of 
stomach cancer are more common among males, 
which might be due to the higher prevalence of risk 
factors, such as smoking, or hormonal factors 
contributing to this difference.2
Although survival rates have generally improved over 
the past several decades, prognosis remains poor.14 The 
5-year survival rate is around 20%, with the notable 
exceptions of 65% in Japan15 and 71·5% in South 
Korea,16 where population screening has led to the 
effective diagnosis of tumours at early stages.17 Given 
this poor survival and the considerable burden 
associated with stomach cancer, we evaluated the 
burden of stomach cancer using the results of the 
Global Burden of Diseases, Injuries, and Risk Factors 
Study (GBD) 2017. We highlight global and regional 
trends that can help to inform global and local 
interventions to lower disease burden and, perhaps, 
curtail the increasing number of incident cases.
Methods
Overview
The methods used for GBD 2017 have been described 
previously and are briefly summarised here.18–21 Cancers 
in GBD 2017 are classified into 29 groups according to 
the International Classification of Diseases 10th edition 
(ICD-10). Stomach cancer included all diagnoses coded 
C16·0–C16·9 (malignant neoplasm of stomach), Z12·0, 
and Z85·02–Z85·028, and did not include tumours of 
gastro-oesophageal junction.22 This study is compliant 
with the Guidelines for Accurate and Transparent Health 
Estimates Reporting.
Data sources
For this study, we used GBD 2017 vital registration 
(19 618 site-years of data), verbal autopsy (374 site-
years), and cancer registry (4474 site-years) data sources 
that provided a representative partial or complete 
sample of incidence or mortality. Information about the 
data sources used for each location in this study can be 
found on the GBD 2017 Data Input Sources Tool 
website. 
Mortality
We derived mortality estimates from the data source 
described above and, when necessary, registry incidence 
data were multiplied by the corresponding, independently 
modelled, mortality-to-incidence ratio to produce 
mortality estimates. Mortality-to-incidence ratios were 
modelled using locations where same-year cancer 
mortality and incidence data were available. The 
mortality-to-incidence ratio model started with a linear-
step mixed-effects model with logit link functions, with 
the Healthcare Access and Quality (HAQ) Index,23 age, 
and sex as covariates. The estimates produced by this 
model were then smoothed over space and time and 
adjusted using spatiotemporal Gaussian process 
regression.24 All the estimates computed from the 
mortality-to-incidence ratios and incidence data were 
used as inputs for a Cause of Death Ensemble model.25 
Potential covariates in these models were selected at 
three levels, pertaining to a possible predictive 
relationship between the covariate and stomach cancer 
mortality. Level 1 covariates (those with a proven strong 
relationship with stomach cancer; eg, biological or 
Research in context
Evidence before this study
The age-standardised incidence and death rates of stomach 
cancer have declined in most parts of the world, but it remains a 
major health problem in many countries. Understanding the 
current burden of stomach cancer and trends across different 
locations is essential for formulating effective preventive 
strategies. The International Agency for Research on Cancer has 
regularly provided cancer estimates in the Global Cancer 
Incidence, Mortality and Prevalence (GLOBOCAN) project; 
however, GLOBOCAN does not provide estimates over time for 
all locations, correlations with risk factors, or estimates for 
disability-adjusted life-years (DALYs). We used estimates from 
the Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 to examine trends of incidence, mortality, and 
burden of disease across 195 countries and territories in seven 
super-regions and 21 regions from 1990 to 2017.
Added value of this study
Using results from GBD 2017, we studied the global, regional, 
and national trends of stomach cancer using comprehensive 
data collected from sources around the world, and reported 
geographical variation and trends over time. Our study adds 
value to the available evidence because, to our knowledge, it 
provides the most comprehensive assessment of the burden of 
stomach cancer by age, sex, socio-demographic status, and 
location over time.
Implications of all the available evidence
Stomach cancer is a significant cause of morbidity and 
mortality in many parts or the world, and the total numbers of 
incident cases and deaths are increasing worldwide. East Asia, 
particularly China, contributes the largest number of incident 
cases, deaths, and DALYs of stomach cancer in the world. The 
age-standardised rates of incidence and death, however, have 
declined steadily, and are much lower than the corresponding 
rates in 1990. The falling rates globally, and within each 
region, are associated with rises in the Socio-demographic 
Index. Our findings provide insight into the changing burden 
of stomach cancer at the global, regional, and national levels, 
which can be used by policy makers to develop 
location-specific programmes aimed at further reducing the 
burden of stomach cancer.
For more on the GBD 2017 Data 
Input Sources Tool see http://
ghdx. healthdata.org/gbd-2017/
data-input-sources
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Incidence Deaths DALYs
Number of incident 
cases
Age-
standardised 
incidence rate 
(per 100 000 
population)
Percentage 
change in 
rates, 
1990–2017
Number of deaths Age-
standardised 
death rate 
(per 100 000 
population)
Percentage 
change in
rates, 
1990–2017
Number of DALYs Age-
standardised 
DALYs rate
(per 100 000 
population)
Percentage 
change in 
rates, 
1990–2017
Global 1 220 662 (1 189 032 
to 1 254 563)
15·4 (15·0 
to 15·8)
–28·0 (–30·5 
to –25·4)
864 989 (848 254 
to 884 655)
11·0 (10·8 
to 11·2)
–43·2 (–45·1 
to –41·4)
19 130 771 (18 738 585 
to 19 569 409)
235·9 (231·1 
to 241·3)
–47·1 (–49·0 
to –45·3)
Males 799 309 (771 025 
to 830 413)
21·7 (21·0 
to 22·6)
–24·0 (–27·0 
to –20·7)
546 441 (530 918 
to 564 028)
15·2 (14·8 
to 15·7)
–41·4 (–43·4 
to –38·9)
12 248 716 (11 898 092 
to 12 645 097)
317·8 (308·8 
to 327·9)
–45·4 (–47·6 
to –43·0)
Females 421 353 (408 084 
to 434 424)
9·9 (9·6 
to 10·2)
–35·6 (–39·3 
to –32·3)
318 548 (309 796 
to 327 854)
7·5 (7·3 
to 7·7)
–46·9 (–50·0 
to –44·4)
6 882 055 (6 683 617 
to 7 083 864)
163·0 (158·3 
to 167·8)
–50·0 (–53·0 
to –47·5)
Andean Latin 
America
8925 (8194 
to 9658)
16·6 (15·2 
to 18·0)
–33·2 (–39·2 
to –26·6)
9130 (8408 
to 9901)
17·1 (15·7 
to 18·5)
–35·9 (–41·4 
to –29·7)
193 905 (176 702 
to 210 939)
353·5 (322·4 
to 384·4)
–38·3 (–44·2 
to –31·9)
Australasia 4263 (3845 
to 4692)
8·8 (7·9 
to 9·7)
–24·9 (–32·4 
to –17·1)
2233 (2052 
to 2429)
4·4 (4·1 
to 4·8)
–47·4 (–51·7 
to –42·8)
39 703 (36 268 
to 43 401)
88·4 (80·7 
to 96·6)
–47·6 (–52·2 
to –42·5)
Caribbean 4033 (3769 
to 4342)
7·9 (7·4 
to 8·5)
–25·2 (–30·4 
to –19·6)
3684 (3438 
to 3966)
7·3 (6·8 
to 7·8)
–34·1 (–38·6 
to –29·3)
83 446 (77 493 
to 90 753)
164·4 (152·5 
to 178·7)
–31·1 (–36·2 
to –25·2)
Central Asia 10 513 (10 059 
to 10 965)
14·1 (13·5 
to 14·7)
–38·9 (–41·6 
to –36·2)
10 331 (9891 
to 10 769)
14·3 (13·8 
to 14·9)
–39·0 (–41·7 
to –36·4)
273 093 (260 966 
to 285 850)
340·0 (325·0 
to 354·6)
–42·7 (–45·3 
to –40·1)
Central Europe 19 794 (19 194 
to 20 462)
9·4 (9·1 
to 9·7)
–43·3 (–45·4 
to –41·2)
18 570 (18 014 
to 19 135)
8·6 (8·4 
to 8·9)
–48·7 (–50·5 
to –46·8)
379 211 (367 809 
to 391 374)
189·9 (184·0 
to 196·0)
–50·0 (–51·8 
to –48·0)
Central Latin 
America
29 601 (28 255 
to 31 008)
12·9 (12·3 
to 13·5)
–16·9 (–20·8 
to –12·7)
21 226 (20 432 
to 22 007)
9·3 (9·0 
to 9·7)
–41·6 (–43·8 
to –39·4)
487 298 (468 124 
to 506 160)
203·8 (195·8 
to 211·7)
–38·9 (–41·4 
to –36·6)
Central 
sub-Saharan 
Africa
3555 (3106 
to 4009)
7·1 (6·3 
to 8·0)
–34·3 (–43·2 
to –24·4)
3551 (3110 
to 3990)
7·6 (6·7 
to 8·5)
–33·9 (–42·7 
to –24·2)
100 529 (87 599 
to 113 903)
173·0 (151·3 
to 195·0)
–34·9 (–44·5 
to –24·0)
East Asia 583 758 (554 933 
to 612 688)
28·6 (27·3 
to 30·0)
–14·7 (–21·5 
to –8·9)
371 288 (356 398 
to 387 201)
18·7 (17·9 
to 19·5)
–44·5 (–48·7 
to –41·0)
8 175 270 (7 834 190 
to 8 543 708)
389·5 (373·5 
to 407·2)
–49·7 (–53·3 
to –46·6)
Eastern Europe 59 809 (57 983 
to 61 663)
17·7 (17·2 
to 18·3)
–39·5 (–41·4 
to –37·5)
43 943 (42 870 
to 45 173)
12·8 (12·5 
to 13·1)
–51·9 (–52·9 
to –50·8)
1 014 257 (987 340 
to 1 043 869)
308·7 (300·7 
to 317·3)
–53·5 (–54·5 
to –52·5)
Eastern 
sub-Saharan 
Africa
10 056 (9361 
to 10 804)
6·4 (5·9 
to 6·8)
–40·2 (–46·5 
to –32·8)
10 087 (9391 
to 10 828)
6·8 (6·3 
to 7·3)
–39·3 (–45·3 
to –32·5)
280 901 (261 364 
to 301 544)
155·8 (145·0 
to 167·4)
–41·9 (–48·7 
to –33·7)
High-income 
Asia Pacific
131 636 (125 691 
to 138 437)
29·5 (28·2 
to 31·0)
–48·7 (–51·1 
to –45·9)
68 042 (65 688 
to 71 099)
14·2 (13·7 
to 14·8)
–56·7 (–58·3 
to –54·7)
1 099 094 (1 056 842 
to 1147 281)
280·0 (268·6 
to 292·3)
–62·4 (–63·8 
to –60·6)
High-income 
North America
39 247 (37 998 
to 40 539)
6·5 (6·3 
to 6·7)
–20·4 (–23·3 
to –17·4)
22 159 (21 591 
to 22 750)
3·6 (3·5 
to 3·7)
–40·0 (–41·7 
to –38·3)
419 819 (407 273 
to 431 498)
74·5 (72·3 
to 76·7)
–39·2 (–41·3 
to –37·2)
North Africa and 
Middle East
35 755 (33 988 
to 37 539)
8·7 (8·3 
to 9·1)
–35·6 (–40·7 
to –29·7)
34 530 (32 838 
to 36 201)
8·8 (8·4 
to 9·2)
–37·4 (–42·1 
to –31·9)
857 927 (809 034 
to 906 399)
189·0 (179·0 
to 198·9)
–42·2 (–46·9 
to –36·5)
Oceania 988 (815 
to 1177)
13·8 (11·7 
to 16·1)
–14·5 (–25·6 
to –3·0)
913 (758 
to 1077)
14·0 (11·9 
to 16·1)
–14·5 (–24·8 
to –3·4)
30 288 (24 766 
to 36 707)
358·4 (297·2 
to 423·6)
–15·4 (–28·2 
to –1·9)
South Asia 96 577 (91 436 
to 101 062)
7·2 (6·8 
to 7·5)
–30·9 (–37·2 
to –25·0)
96 652 (91 276 
to 101 052)
7·5 (7·0 
to 7·8)
–30·2 (–36·6 
to –24·6)
2 626 634 (2 487 690 
to 2 747 242)
178·2 (168·5 
to 186·2)
–33·0 (–39·4 
to –27·3)
Southeast Asia 39 191 (36 559 
to 42 265)
6·8 (6·4 
to 7·3)
–43·8 (–49·0 
to –38·2)
38 871 (36 283 
to 41 869)
7·0 (6·6 
to 7·6)
–44·7 (–49·7 
to –39·4)
960 904 (893 460 
to 1038 037)
154·1 (143·5 
to 166·3)
–48·1 (–53·3 
to –42·3)
Southern Latin 
America
10 145 (9436 
to 10 956)
12·4 (11·5 
to 13·4)
–34·1 (–39·0 
to –28·5)
10 203 (9515 
to 10 988)
12·3 (11·5 
to 13·2)
–38·3 (–42·8 
to –33·1)
203 392 (188 154 
to 220 430)
253·8 (234·7 
to 275·1)
–40·4 (–45·0 
to –35·0)
Southern 
sub-Saharan 
Africa
2839 (2706 
to 2979)
5·2 (5·0 
to 5·4)
–27·3 (–32·3 
to –22·2)
2910 (2779 
to 3052)
5·5 (5·3 
to 5·8)
–26·2 (–31·3 
to –21·0)
73 206 (69 472 
to 77 098)
123·3 (117·3 
to 129·6)
–30·7 (–35·8 
to –25·5)
Tropical Latin 
America
21 823 (21 369 
to 22 331)
9·5 (9·3 
to 9·7)
–40·2 (–41·8 
to –38·5)
21 140 (20 734 
to 21 550)
9·3 (9·1 
to 9·4)
–44·9 (–46·3 
to –43·6)
482 998 (473 844 
 to 492 741)
203·0 (199·3 
to 207·1)
–44·1 (–45·6 
to –42·8)
Western Europe 95 266 (90 462 
to 100 111)
10·5 (10·0 
to 11·0)
–37·4 (–40·6 
to –34·2)
62 213 (59 851 
to 64 525)
6·4 (6·2 
to 6·7)
–54·3 (–56·0 
to –52·6)
1 025 787 (984 851 
to 1 066 633)
125·4 (120·2 
to 130·4)
–55·1 (–56·9 
to –53·3)
Western 
sub-Saharan 
Africa
12 890 (11 719 
to 14 193)
7·7 (7·1 
to 8·5)
–20·5 (–27·9 
to –11·3)
13 311 (12 153 
to 14 701)
8·4 (7·7 
to 9·2)
–19·5 (–27·1 
to –9·9)
323 109 (293 082 
to 359 119)
167·9 (152·9 
to 185·7)
–23·8 (–30·9 
to –14·8)
Data in parentheses are 95% uncertainty intervals. DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Table: Incident cases of deaths and DALYs of stomach cancer in 2017, and percentage change of age-standardised rates by sex and GBD region
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causative link) included smoking prevalence, mean 
cigarettes per capita, cumulative cigarettes (5, 10, 15, and 
20 mean pack-years), diet high in sodium, log-
transformed summary exposure value (SEV) scalar for 
stomach cancer, SEV of unsafe water, and SEV of unsafe 
sanitation. Level 2 covariates (strong relationship without 
a direct biological link) were mean body-mass index, 
indoor air pollution (all cooking fuels), outdoor air 
pollution (particulate matter concentration of 2·5 µm 
dimeter), HAQ Index, adjusted fruit and vegetable intake 
(grams), sanitation (proportion with access), and 
improved water source (proportion with access). Finally, 
Level 3 (more distal covariates mediated through Level 1 
or 2 covariates) included education (years per capita), lag-
distributed income (US$ per capita), and Socio-
demographic Index (SDI).
Non-fatal modelling
The final mortality estimates were divided by the 
estimated mortality-to-incidence ratios to compute 
stomach cancer incidence. Disability-adjusted life-years 
(DALYs) were calculated by summing years lived with 
disability (YLDs) and years of life lost (YLLs). The 
contributions of YLDs and YLLs to stomach cancer DALYs 
were 2% and 98%, respectively. YLDs were estimated by 
classifying 10-year cancer prevalence into four sequelae 
and multiplying these prevalences by corresponding 
disability weights: diagnosis and treatment, remission, 
disseminated and metastatic, and terminal phase. The 
durations of the four prevalence phases for stomach 
cancer were 5·2 months26 of diagnosis and treatment, 
3·88 months27 of disseminated and metastatic disease, 
and 1 month of terminal phase. Remission durations 
were calculated on the basis of the remainder of time 
after attributing other sequelae. The YLLs were estimated 
by multiplying the estimated number of deaths by age 
with a standard life expectancy at that age. Details of 
estimation methods and data sources have been published 
before.22
Rates were standardised to the GBD world population 
and reported per 100 000 population as age-standardised 
incidence rates, age-standardised death rates, and age-
standardised DALY rates. All estimates were generated 
with 95% uncertainty intervals (UIs), including all 
sources of uncertainty arising from measurement error, 
biases, and modelling. The 95% UIs were derived from 
the 2·5th and 97·5th percentiles of 1000 draws.
SDI and risk factors
Risk factor quantification was based on the GBD 2017 
comparative risk assessment described earlier.18 The SDI 
is a composite indicator of socio-development status that 
includes fertility, education, and income, and which has 
shown a strong association with health outcomes. SDI 
ranges from zero (worst) to one (best).22 We used linear 
correlation and fitted regression lines to determine the 
relationship between countries’ development level 
(ie, SDI) and incidence, death, and DALY rates of 
stomach cancer. We reported the percentage of DALYs 
due to stomach cancer that were attributable to high-
sodium diet and smoking by multiplying stomach 
cancer DALYs by the risk factor’s population attributable 
fraction for a given age, sex, location, and year.18
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to the 
data in the study and had final responsibility for the 
decision to submit for publication.
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Figure 1: The age-standardised incidence (A) and death (B) rates of stomach cancer in 2017 for 21 GBD 
regions, by sex
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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Results
In 2017, more than 1·22 million (95% UI 1·19–1·25) 
incident cases of stomach cancer occurred worldwide, 
and nearly 865 000 people (848 000–885 000) died of 
stomach cancer (table). The age-standardised incidence 
rate of stomach cancer was 15·4 per 100 000 population 
(15·0–15·8), with an age-standardised death rate of 11·0 
per 100 000 population (10·8–11·2). Stomach cancer 
contributed to 19·1 million (18·7–19·6) DALYs worldwide 
in 2017. For males, both the age-standardised incidence 
and death rates of stomach cancer were more than twice 
the rates for females (21·7 [21·0–22·6] vs 9·9 [9·6–10·2], 
and 15·2 [14·8–15·7] vs 7·5 [7·3–7·7] per 100 000 
population, respectively). The male–female incidence 
and death gap existed in all regions, but was narrower in 
Andean Latin America and south Asia (figure 1). Specific 
country and territory data for incidence, deaths, and 
DALYs can be found in the appendix (p 2–25).
The world map of age-standardised incidence rates of 
stomach cancer in 2017 is shown in figure 2. The highest 
age-standardised incidence rate was seen in the high-
income Asia Pacific region (29·5 per 100 000 population 
[95% UI 28·2–31·0]), particularly in Japan and South 
Korea, and east Asia (28·6 per 100 000 population 
[27·3–30·0]; table; appendix pp 2–9, 18–25). In east 
Asia, China alone had nearly half of the global 
incident cases in 2017 (562 000 [533 000–591 000]), and 
contributed to 7·8 million (7·5–8·2) DALYs (appendix 
pp 2–9, 18–25). The eastern Europe (17·7 [17·2–18·3]) 
and Andean Latin America (16·6 [15·2–18·0]) regions 
had the next highest age-standardised incidence rates. 
Two countries outside these high-incidence regions—
Mongolia (35·6 [31·9–39·6]) and Afghanistan (32·8, 
[26·5–39·6])—had the overall highest age-standardised 
incidence rates. The lowest incidence rates were seen in 
southern and eastern sub-Saharan Africa and high-
income North America (table). East Asia had the highest 
age-standardised death rate (18·7 [17·9–19·5]), followed 
by Andean Latin America (17·1 [15·7–18·5]) and central 
Asia (14·3 [13·8–14·9]). The high-income Asia Pacific 
region, which ranked first in age-standardised incidence 
rate, had the fourth highest age-standardised death rate 
and the sixth highest DALY rate among all GBD regions 
in 2017. The two countries with the highest age-
standardised incidence rate also had the highest age-
standardised death rates: Mongolia (37·6 [33·8–41·8]) 
and Afghanistan (33·6 [27·2–40·2]). The lowest age-
standardised death rates were seen in high-income 
North America and Australasia.
Compared with 1990, in 2017 the number of incident 
cases of stomach cancer increased from about 864 000 
(95% UI 847 000–890 000) to 1·22 million (1·19–1·25; 
appendix p 2)—an increase of around 356 000 cases. The 
number of deaths increased from around 769 000 
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(752 000–795 000) to 865 000 (848 000–885 000; appendix 
p 10)—ie, an increase of around 96 000 deaths. But 
stomach cancer contributed to almost the same number 
of DALYs in 2017 as in 1990 (appendix pp 18–25). The 
majority of increases in the absolute number of cases and 
deaths came from east Asia: from 1990 to 2017, incident 
cases rose from about 308 000 (296 000–326 000) to almost 
584 000 (555 000–613 000) and the number of deaths 
increased from around 296 000 (285 000–313 000) to more 
than 371 000 (356 000–387 000). Again, the bulk of these 
increases occurred in China (appendix pp 2–17). Other 
regions that made large contributions to increased 
numbers of cases and deaths included south Asia, central 
Latin America, and north Africa and the Middle East 
(figure 3). In high-income Asia Pacific countries, the 
number of incident cases increased from over 117 000 
(115 000–119 000) to almost 132 000 (126 000–138 000), but 
the number of deaths due to stomach cancer showed very 
little change in the same period (66 000 [65 300–66 800] in 
1990 to 68 000 [65 700–71 100] in 2017; appendix pp 2–17). 
Both the number of incident cases and number of deaths 
due to stomach cancer decreased in European regions 
(central, eastern, and western) between 1990 and 2017.
Despite the increases in absolute numbers, the global 
age-standardised incidence and death rates of stomach 
cancer decreased compared with 1990 (figure 4). During 
this period, the age-standardised incidence rate decreased 
by 28·0% (95% UI 25·4–30·5) globally, while the age-
standardised death rate dropped at a faster rate of 43·2% 
(41·0–45·1), and age-standaradised DALY rate by 47·1% 
(45·3–49·0; table; figure 4). The downward trend in age-
standardised incidence rates did, however, plateau at the 
global level and for some regions in the last 5 years of the 
study period. The decreases in age-standardised incidence 
and mortality from 1990 to 2017 were greater for females 
than for males at the global level and in many regions 
(appendix pp 31–32). The high-income Asia Pacific region 
had the sharpest drop in age-standardised rates between 
1990 and 2017 compared with all other regions (decrease 
in age-standardised incidence by 48·7% [45·9–51·1]; age-
standardised deaths by 56·7% [54·7–58·3]; and age-
standardised DALYs by 62·4% [60·6–63·8]). In east Asia, 
the drop in age-standardised incidence rate was not as 
sharp (14·7% [8·9–21·5]); however, a 44·5% (41·2–48·7) 
decrease in age-standardised deaths caused the age-
standardised DALY rate to reduce by nearly half (49·7%, 
46·6–53·3; table).
The percentage of age-standardised DALYs attributable 
to high-sodium diet and smoking in each region are 
shown in figure 5. Globally, 38·2% (95% UI 21·1–57·8) 
of the age-standardised DALYs were attributable to a 
high-sodium diet, which was moderately higher in males 
than in females (41·2% [23·6–60·9] for males; and 
32·7% [16·4–52·7] for females). In east Asia, this figure 
was almost twice that of all other regions, with 61·3% 
(42·8–78·2) of age-standardised DALYs attributable to a 
high-sodium diet. For males, 24·5% (20·0–28·9) of the 
age-standardised DALYs globally were attributable to 
smoking. Eastern Europe (33·0%, 27·5–37·9) and east 
Asia (29·0%, 23·5–34·2) had the highest percentage of 
age-standardised DALYs attributable to smoking among 
males. In females, smoking did not account for a sizeable 
fraction of age-standardised DALYs globally, but in parts 
of Europe (particularly western and central), high-income 
North America, Australasia, and parts of Latin America 
(particularly tropical and southern), the contribution of 
smoking to stomach cancer age-standardised DALYs 
among females was higher than 10%.
Discussion
Stomach cancer is an important cause of morbidity and 
mortality in many parts or the world, and the total 
numbers of incident cases and deaths are increasing 
worldwide. East Asia, particularly China, contributes the 
largest number of incident cases, deaths, and DALYs from 
stomach cancer globally. However, the age-standardised 
incidence and death rates have declined steadily.
1990 1995 2000 2005 2010 2015
0
200 000
400 000
600 000
800 000
1 000 000
1 200 000
B
N
um
be
r o
f d
ea
th
s
0
200 000
100 000
400 000
300 000
600 000
700 000
500 000
800 000
900 000
1 000 000
A
N
um
be
r o
f i
nc
id
en
t c
as
es
Year
Southern sub-Saharan AfricaCentral sub-Saharan Africa
Eastern sub-Saharan AfricaWestern sub-Saharan AfricaOceaniaEast Asia
Southeast AsiaSouth AsiaNorth Africa and Middle EastCentral Asia
Eastern EuropeCentral EuropeCaribbeanSouthern Latin America
Central Latin AmericaTropical Latin AmericaAndean Latin AmericaAustralasia
Western EuropeHigh-income North AmericaHigh-income Asia Pacific
Figure 3: Absolute number of incident cases of (A) and deaths due to (B) stomach cancer, 1990 to 2017, for 
21 GBD regions
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
Articles
48 www.thelancet.com/gastrohep   Vol 5   January 2020
Our findings generally agree with those of the Global 
Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 
project,28 although our estimates were somewhat higher 
than theirs, possibly as a result of differences in data 
sources and estimation methods. From 1990 to 2017, 
stomach cancer dropped from the fifth leading incident 
cancer worldwide to the seventh, and from the second 
leading cause of cancer deaths to third (after lung and 
colorectal cancers).22 As a result, stomach cancer accounts 
for the third highest cancer-related DALYs after lung and 
liver cancers. However, this decline in burden relative to 
other cancers and the dramatic decline in age-standardised 
rates have not necessarily led to a lower burden of stomach 
cancer on the health systems in high-risk countries. This 
is because changes in the population age structure and 
population growth have meant that numbers of incident 
cases and deaths of stomach cancer have continued to 
increase in many locations.22 Based on our findings, a 
further decrease in the absolute number of cases and 
deaths could be possible if the rates in east Asia, where 
almost half of the incident cases and deaths occur, are 
further reduced.
Based on migrant studies29 and the secular trends in 
stomach cancer rates, environmental factors are thought 
to play a significant role in the pathogenesis of stomach 
cancer.3 In contrast, only about 10% of cases aggregate in 
families, and only 1–3% occur as part of known hereditary 
syndromes.1 Our results suggest lifestyle factors play a 
significant role in stomach cancer burden, in particular 
high-sodium diet in east Asian populations and smoking 
among males. Both of these are also risk factors for other 
non-communicable diseases30 and minimal exposure to 
them is generally suggested in guidelines for a healthy 
lifestyle. Reducing high-salt foods in the diet is one of the 
ways proposed to tackle the stomach cancer problem in 
high-risk Asian countries.31
H pylori infection is the most important established risk 
factor for stomach cancer, and, as a result, most of the 
prevention strategies against this cancer focus on this 
infection. H pylori was once a ubiquitous infection,32 and 
in populations where infection rates are high, stomach 
cancer is a significant public health problem despite other 
interventions.3,33 In some countries in western Europe 
(eg, Germany, the UK, and Spain) and in the USA, the 
previously declining burden of stomach cancer has 
plateaued, especially in the middle-aged (ie, 50–64 years) 
population, probably due to a low and stable prevalence of 
H pylori infection.34 For our study, we were unable to 
evaluate the role of H pylori infection in stomach cancer 
burden: such data are not included in registries and 
population-level data sources because they are costly and 
difficult to obtain at large scales. However, most of the risk 
reduction due to improved socio-economic status (even in 
the absence of specific preventive strategies) is thought to 
stem from reduced H pylori infection rates.35 Beyond 
general sanitation and improved socio-economic status, 
H pylori can also be effectively eradicated by different drug 
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regimens. There is some controversy over whether 
population eradication of H pylori would be a cost-effective 
strategy to lower the burden of stomach cancer, and a trial 
to address this question would be logistically challenging 
and resource-intensive because of the period required for 
follow-up. In a systematic review and meta-analysis, Lee 
and colleagues36 reported that mass eradication of H pylori 
infection was associated with a reduced incidence of 
stomach cancer. They concluded that the benefit of 
eradication was dependent on the stomach cancer risk at 
baseline. In another meta-analysis,37 Ford and colleagues 
limited their study to randomised controlled trials and 
showed limited, moderate-quality evidence for reduced 
incidence of stomach cancer associated with screening for 
and eradicating H pylori in healthy asymptomatic infected 
individuals from Asia. This study concluded that these 
results might not necessarily be generalisable to other 
populations.
We found that reductions in age-standardised incidence 
rates did not necessarily parallel those of age-
standardised death and DALY rates, meaning that while 
age-standardised death rates fell considerably in many 
locations, age-standardised incidence rates decreased 
more slowly. For example, east Asia, particularly China, 
witnessed a relatively small decrease in age-standardised 
incidence rates over the study period, whereas the 
decreases in age-standardised death and attributable 
DALY rates were much larger. A study of cancer registries 
in China showed that the disparity in cancer mortality 
rates was far greater than cancer incidence when rural and 
urban areas were compared.38 The authors suggested that 
this disparity was due to limited medical resources, lower 
levels of cancer care, and a larger proportion of patients 
diagnosed with cancer at a late stage in rural and 
underdeveloped areas. China has taken steps to reduce 
the cancer care disparities between rural and urban 
areas,39 and we think these efforts might explain the sharp 
decrease in death rates due to stomach cancer. Another 
successful strategy to reduce deaths due to stomach cancer 
has been used in Japan and South Korea, two of the high-
income Asia Pacific countries. These countries have 
implemented population screening programmes leading 
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to early detection of cancer cases40 and better survival 
rates. This has led some investigators to believe that China 
should adopt a similar strategy to further reduce the 
burden of stomach cancer.41 But population screening for 
stomach cancer includes invasive methods, and its 
feasibility and cost-effectiveness outside high-risk regions 
have never been investigated.2 A serum pepsinogen test 
combined with H pylori testing has been suggested as a 
potential method to triage suitable candidates for more 
invasive screening methods, but evidence for their clinical 
application is still mainly limited to Japanese popu-
lations.42Although regional patterns convey a lot of useful 
information about the distribution of stomach cancer 
burden and its trends and correlates, significant variations 
exist within each region. For example, stomach cancer 
incidence rates in Canada are almost double those in 
the USA, and stomach cancer contributes to more age-
standardised DALYs per 100 000 population in Portugal, 
Chile, Guatemala, Bolivia, Haiti, Zimbabwe, and Mali 
than in other countries in the same regions. In addition, 
the two countries with the highest age-standardised 
incidence, death, and DALY rates globally (Mongolia and 
Afghanistan) have much higher rates than those of their 
respective regions (central Asia, and north Africa and 
Middle East, respectively). While making such 
comparisons, it is important to note that data quality 
differs across individual countries, and GBD uses a rating 
system (from zero to five stars) to assess the quality of the 
available data from each country.43 In addition to data 
quality, differences in data collection and coding systems 
are other challenges facing such comparisons.
A major limitation of our study was the inability to 
distinguish cardia and non-cardia forms of stomach cancer. 
Non-cardia stomach cancer is predominantly associated 
with H pylori infection and is probably the main reason for 
the changing rates of stomach cancer across the world.4 
Cardia tumours are estimated to account for about 12% of 
stomach cancers globally, but are responsible for a higher 
proportion of stomach cancer burden in some low-risk 
populations.44 Cardia cancer in the USA is more common 
among the non-Hispanic white population and is not 
strongly linked to socio-economic status.45 Comparing 
different populations and studying the secular trends of 
cardia versus non-cardia tumours over time is complex, 
because the definition of cardia cancer has evolved over 
time, and some cardia tumours might have been classified 
as lower oesophageal adenocarcinomas, and vice versa.8 We 
could not determine the burden of stomach cancer directly 
attributable to H pylori, as described above, and the lack of 
data on some of the other risk factors limited our risk factor 
analysis. We also did not have information on the molecular 
subtypes of stomach tumours.46 As a general limitation of 
GBD, we relied on estimates from the modelling process 
for locations where data had low levels of completeness. 
But, by providing comprehensive measures of uncertainty, 
the degree of error in the estimates resulting from data 
scarcity is clarified.
Beyond general improvements in socio-economic 
status leading to improved health and lower H pylori 
infection rates, specific local strategies are needed to 
further reduce the number of incident cases and deaths 
due to stomach cancer, and these should be tailored to 
each country’s risk factor profile. Targeting the risk 
factors that affect stomach cancer incidence and mortality 
(such as smoking and diet), in addition to country-
specific feasible and cost-effective interventions aimed at 
lowering H pylori infection rates, early detection of 
suspected cases, and improved access to standard 
treatment facilities, can be among such strategies. By 
providing annual updates to regional and country-level 
stomach cancer estimates, future iterations of GBD will 
be useful for monitoring the success of such strategies.
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